VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Thursday morning. The brokerage issued a sell rating on the stock.

Other analysts have also recently issued research reports about the company. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reissued a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a report on Wednesday, January 8th.

VolitionRx Stock Up 2.3 %

Shares of VolitionRx stock opened at $0.63 on Thursday. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.23. The company has a fifty day moving average of $0.64 and a 200 day moving average of $0.66.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the transaction, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. This represents a 39.51 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Cameron John Reynolds purchased 139,811 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average price of $0.57 per share, with a total value of $79,692.27. Following the transaction, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at $1,206,920.28. This represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 358,266 shares of company stock worth $204,212 in the last quarter. 12.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC boosted its stake in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 730,448 shares of the company’s stock after buying an additional 95,900 shares during the period. Geode Capital Management LLC owned approximately 0.79% of VolitionRx worth $439,000 at the end of the most recent quarter. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.